Role of biomarkers in patients with dyspnea

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 2, 2011, Pages 229-240

  Gori, C S ^a   Magrini, L ^a   Travaglino, F ^a   Di Somma, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomarkers; Copeptin and D dimer; Dyspnea; Emergency department; MR proADM; MR proANP; Natriuretic peptides; Procalcitonin; Troponins

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; D DIMER; HORMONE PRECURSOR; PROADRENOMEDULLIN; PROCALCITONIN; TROPONIN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; BACTERIAL INFECTION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DYSPNEA; EMERGENCY WARD; HEART FAILURE; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SEPSIS;

ACUTE DISEASE; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CALCITONIN; DYSPNEA; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; TROPONIN T;

EID: 79953254639     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. SHIBER JR, SANTANA J. Dyspnea. Med Clin N Am 2006; 90: 453-479.
2. WASSERMAN K, CASABURI R. Dyspnea: physiological and pathophysiological mechanisms. Annu Rev Med 1988; 39: 503-515.
3. WRIGHT GW, BANSCOMB BV. The origin of the sensations of dyspnea. Trans Am Clin Climatol Assoc 1954; 66: 116-125.
4. DYSPNEA. Mechanism, assessment and managment: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med; 1999; 159: 321-340.
5. SINGER AJ, THODE HC JR, GREEN GB, BIRKHAHN R, SHAPIRO NI, CAIRNS C, BAUMANN BM, AGHABABIAN R, CHAR D, HOLLANDER JE. The incremental benefit of a shortness-of-breath biomarker panel in emergency department patients with dyspnea. Acad Emerg Med 2009; 16: 488-494.
6. DYSPNEA. Fear, loathing and physiology. Emerg Med Pract 1999; 3: 1-20.
7. TINTINALLI JE, KELEN GD, STAPCZYNSKI JS. Emergency Medicine. Sixth ed. McGraw-Hill; 2004.
8. RAO AB, GRAY. Breathlessness in hospitalised adult patients. Postgrad Med J 2003; 79: 681-685.
9. CACERES L, COOKE D, ZALENSKI R, RYDMAN R, LAKIER JB. Myocardial infarction with an initially normal electrocardiogram-angiographic findings. Clin Cardiol 1995; 18: 563-568.
10. POPE JH, AUFDERHEIDE TP, RUTHAZER R, WOOLARD RH, FELDMAN JA, BESHANSKY JR, GRIFFITH JL, SELKER HP. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 20; 342: 1163-1170.
11. ) BLANKE H, COHEN M, SCHLUETER GU, KARSCH KR, RENTROP KP. Electrocardiographic and coronary arteriographic correlations during acute myocardial infarction. Am J Cardiol 1984; 54: 249-255.
12. WRIGHT J, JARMAN R, CONNOLLY J, DISSMANN P. Echocardiography in the emergency department. Emerg Med J 2009; 26: 82-86.
13. WILLIAMS AJ. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. Br Med J 1998; 317: 1213-1216.
14. STEIN PD, HULL RD. Multidetector computed tomography for the diagnosis of acute pulmonary embolism. Curr Opin Pulm Med 2007; 13: 384-388.
15. MUELLER C, SCHOLER A, LAULE-KILIAN K, MARTINA B, SCHINDLER C, BUSER P, PFISTERER M, PERRUCHOUD A. Use of B-Type Natriuretic Peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-654.
16. HIROSE S, HAGIWARA H, TAKEI Y. Comparative molecular biology of natriuretic peptide receptors. Can J Physiol Pharmacol 2001; 79: 665-672.
17. TASK FORCE FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE. European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 2217-2218.
18. BHALLA V, WILLIS S, MAISEL AS. B-type natriuretic peptide: the level and the drug-partners in the diagnosis of congestive heart failure. Congest Heart Fail 2004; 10(1 Suppl 1): 3-27.
19. MAISEL AS, KRISHNASWAMY P, NOWAK RM, MCCORD J, HOLLANDER JE, DUC P, OMLAND T, STORROW AB, ABRAHAM WT, WU AH, CLOPTON P, STEG PG, WESTHEIM A, KNUDSEN CW, PEREZ A, KAZANEGRA R, HERRMANN HC, MCCULLOUGH PA; BREATHING NOT PROPERLY MULTINATIONAL STUDY INVESTIGATORS. Rapid measurement of B-typee natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167.
20. MAISEL A, MUELLER C, ADAMS K JR, ANKER SD, ASPROMONTE N, CLELAND JG, COHEN-SOLAL A, DAHLSTROM U, DEMARIA A, DI SOMMA S, FILIPPATOS GS, FONAROW GC, JOURDAIN P, KOMAJDA M, LIU PP, MCDONAGH T, MCDONALD K, MEBAZAA A, NIEMINEN MS, PEACOCK WF, TUBARO M, VALLE R, VANDERHYDEN M, YANCY CW, ZANNAD F, BRAUNWALD E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839.
21. JOUGASAKI M, BURNETT JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66: 855-872.
22. JOUGASAKI M, RODEHEFFER RJ, REDFIELD MM, YAMAMOTO K, WEI CM, MCKINLEY LJ, BURNETT JC Jr. Cardiac secretion of adrenomeduilin in human heart failure. J Clin Invest 1996; 97: 2370-2376.
23. NISHIKIMI T, SAITO Y, KITAMURA KI, ISHIMITSU T, ETO T, KANGAWA K, MATSUO H, OMAE T, MATSUOKA H. Increased plasma levels of adrenomeduilin in patients with heart failure. J Am Coll Cardiol 1995; 26: 1424-1431.
24. NISHIO K, AKAI Y, MURAO Y, DOI N, UEDA S, TABUSE H, MIYAMOTO S, DOHI K, MINAMINO N, SHOJI H, KITAMURA K, KANGAWA K, MATSUO H. Increased plasma concentrations of adrenomeduilin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 1997; 25: 953-957.
25. MORGENTHALER NG, STRUCK J, ALONSO C, BERGMANN A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823-1829.
26. POTOCKI M, BREIDTHARDT T, REICHLIN T, MORGENTHALER NG, BERGMANN A, NOVEANU M, SCHAUB N, UTHOFF H, FREIDANK H, BUSER L, BINGISSER R, CHRIST M, MEBAZAA A, MUELLER C. Midregional proadrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009; 13: R122.
27. CHRIST-CRAIN M, MORGENTHALER NG, STRUCK J, HARBARTH S, BERGMANN A, MÜLLER B. Mid-regional proadrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9: R816- 824.
28. CHRIST-CRAIN M, MORGENTHALER NG, STOLZ D, MÜLLER C, BINGISSER R, HARBARTH S, TAMM M, STRUCK J, BERGMANN A, MÜLLER B. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96.
29. STOLZ D, CHRIST-CRAIN M, MORGENTHALER NG, MIEDINGER D, LEUPPI J, MÜLLER C, BINGISSER R, STRUCK J, MÜLLER B, TAMM M. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134: 263-272.
30. KHAN SQ, O'BRIEN RJ, STRUCK J, QUINN P, MORGENTHALER N, SQUIRE I, DAVIES J, BERGMANN A, NG LL. Prognostic value of midregional proadrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007; 49: 1525-1532.
31. GEGENHUBER A, STRUCK J, DIEPLINGER B, POELZ W, PACHER R, MORGENTHALER NG, BERGMANN A, HALTMAYER M, MUELLER T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007; 13: 42-49.
32. MAISEL A, MUELLER C, NOWAK R, PEACOCK WF, LANDSBERG JW, PONIKOWSKI P, MOCKEL M, HOGAN C, WU AH, RICHARDS M, CLOPTON P, FILIPPATOS GS, DI SOMMA S, ANAND I, NG L, DANIELS LB, NEATH SX, CHRISTENSON R, POTOCKI M, MCCORD J, TERRACCIANO G, KREMASTINOS D, HARTMANN O, VON HAEHLING S, BERGMANN A, MORGENTHALER NG, ANKER SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55: 2062-2076.
33. POTTER LR, YODER AR, FLORA DR, ANTOS LK, DICKEY DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; 191: 341-366.
34. WOODARD GE, ROSADO JA. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol 2008; 268: 59-93.
35. Venugopal J. Cardiac natriuretic peptides-hope or hype? J Clin Pharm Ther 2001; 26: 15-31.
36. BUCKLEY MG, MARCUS NJ, YACOUB MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999; 97: 689-695.
37. CAPPELLIN E, GATTI R, SPINELLA P, DE PALO CB, WOLOSZCZUK W, MARAGNO I, DE PALO EF. Plasma atrial natriuretic peptide (ANP) fragments proANP (1- 30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta 2001; 310: 49-52.
38. DAGGUBATI S, PARKS JR, OVERTON RM, CINTRON G, SCHOCKEN DD, VESELY DL. Adrenomeduilin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997; 36: 246-255.
39. MORGENTHALER NG, STRUCK J, THOMAS B, BERGMANN A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
40. GEGENHUBER A, STRUCK J, POELZ W, PACHER R, MORGENTHALER NG, BERGMANN A, HALTMAYER M, MUELLER T. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006; 52: 827-831.
41. PRAT C, LACOMA A, DOMINGUEZ J, PAPASSOTIRIOU J, MORGENTHALER NG, ANDREO F, TUDELA P, RUIZ-MANZANO J, AUSINA V. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007; 55: 400-407.
42. MÜLLER B, SÜESS E, SCHUETZ P, MÜLLER C, BINGISSER R, BERGMANN A, STOLZ D, TAMM M, MORGENTHALER NG, CHRIST-CRAIN M. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260: 568-576.
43. SELIGMAN R, PAPASSOTIRIOU J, MORGENTHALER NG, MEISNER M, TEIXEIRA PJ. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084-2091.
44. BEISHUIZEN A, HARTEMINK KJ, VERMES I, GROENEVELD AJ. Circulating cardiovascular markers and mediators in acute illness: an update. Clin Chim Acta 2005; 354: 21-34.
45. MORGENTHALER NG, STRUCK J, CHRIST-CRAIN M, BERGMANN A, MULLER B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005; 9: R37-45.
46. KATAN M, FLURI F, SCHUETZ P, MORGENTHALER NG, ZWEIFEL C, BINGISSER R, KAPPOS L, STECK A, ENGELTER ST, MÜLLER B, CHRIST-CRAIN M. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010; 56: 1045-1053.
47. LEE TH, ROUAN GW, WEISBERG MC, BRAND DA, COOK EF, ACAMPORA D, GOLDMAN L. Sensitivity of routine clinical criteria for diagnosing myocardial infarction within 24 hours of hospitalization. Ann Intern Med 1987; 106: 181-186.
48. TAKEDA S, YAMASHITA A, MAEDA K, MAÉDA Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature 2003; 424(6944): 35-41.
49. CUMMINS P, PERRY SV. Troponin I from human skeletal and cardiac muscles. Biochem J 1978; 171: 251-259.
50. ALPERT JS, THYGESEN K, JAFFE A, WHITE HD. The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. Heart 2008; 94: 1335-1341.
51. APPLE FS. Clinical and analytical standardization issues confronting cardiac troponin I. Clin Chem 1999; 45: 18-20.
52. MAIR J, PUSCHENDORF B, MICHEL G. Clinical significance of cardiac contractile proteins for the diagnosis of myocardial injury. Adv Clin Chem 1994; 31: 63-98.
53. EGGERS KM, OLDGREN J, NORDENSKJÖLD A, LINDAHL B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004; 148: 574-581.
54. MAIR P, MAIR J, KOLLER J, WIESER C, ARTNER-DWORZAK E, PUSCHENDORF B. Cardiac troponin T in the diagnosis of heart contusion. Lancet 1991; 338(8768): 693.
55. LUND M, FRENCH JK, JOHNSON RN, WILLIAMS BF, WHITE HD. Serum troponins T and I after elective cardioversion. Eur Heart J 2000; 21: 245-253.
56. MÜLLNER M, HIRSCHL MM, HERKNER H, STERZ F, LEITHA T, EXNER M, BINDER M, LAGGNER AN. Creatine kinase-mb fraction and cardiac troponin T to diagnose acute myocardial infarction after cardiopulmonary resuscitation. J Am Coll Cardiol 1996; 28: 1220-1225.
57. VER ELST KM, SPAPEN HD, NGUYEN DN, GARBAR C, HUYGHENS LP, GORUS FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650-657.
58. MEYER T, BINDER L, HRUSKA N, LUTHE H, BUCHWALD AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36: 1632-1636.
59. MISSOV E, CALZOLARI C, PAU B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96: 2953-2958.
60. PEACOCK WF 4TH, DE MARCO T, FONAROW GC, DIERCKS D, WYNNE J, APPLE FS, WU AH; ADHERE INVESTIGATORS. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-2126.
61. REICHLIN T, HOCHHOLZER W, BASSETTI S, STEUER S, STELZIG C, HARTWIGER S, BIEDERT S, SCHAUB N, BUERGE C, POTOCKI M, NOVEANU M, BREIDTHARDT T, TWERENBOLD R, WINKLER K, BINGISSER R, MUELLER C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858-867.
62. LIEBERMAN D, LIEBERMAN D, GELFER Y, VARSHAVSKY R, DVOSKIN B, LEINONEN M, FRIEDMAN MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-1270.
63. SPAPEN HD, HACHIMI-IDRISSI S, CORNE L, HUYGHENS LP. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg 2006; 61: 138-142.
64. GOGOS CA, DROSOU E, BASSARIS HP, SKOUTELIS A. Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176-180.
65. SIMON L, GAUVIN F, AMRE DK, SAINT-LOUIS P, LACROIX J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217.
66. HAEUPTLE J, ZABORSKY R, FIUMEFREDDO R, TRAMPUZ A, STEFFEN I, FREI R, CHRIST-CRAIN M, MÜLLER B, SCHUETZ P. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 55-60.
67. JENSEN JU, HESLET L, JENSEN TH, ESPERSEN K, STEFFENSEN P, TVEDE M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-602.
68. BOECK L, EGGIMANN P, SMYRNIOS N, PARGGER H, THAKKAR N, SIEGEMUND M, MARSCH S, RAKIC J, TAMM M, STOLZ D. MR-proANP and procalcitonin improve survival prediction in ventilator associated pneumonia. Eur Respir J; 2010 Jun 7. [Epub ahead of print]
69. NOBRE V, HARBARTH S, GRAF JD, ROHNER P, PUGIN J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
70. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B; ProHOSP study group. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7: 102.
71. SCHUETZ P, ALBRICH W, CHRIST-CRAIN M, CHASTRE J, MUELLER B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010; 8: 575-587.
72. KELLY D, KHAN SQ, DHILLON O, QUINN P, STRUCK J, SQUIRE IB, DAVIES JE, NG LL. Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers 2010; 15: 325-331.
73. LAND H, SCHÜTZ G, SCHMALE H, RICHTER D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982; 295(5847): 299-303.
74. MORGENTHALER NG, STRUCK J, ALONSO C, BERGMANN A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
75. STOISER B, MÖRTL D, HÜLSMANN M, BERGER R, STRUCK J, MORGENTHALER NG, BERGMANN A, PACHER R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 771-778.
76. KHAN SQ, DHILLON OS, O'BRIEN RJ, STRUCK J, QUINN PA, MORGENTHALER NG, SQUIRE IB, DAVIES JE, BERGMANN A, NG LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115: 2103-2110.
77. MÜLLER B, MORGENTHALER N, STOLZ D, SCHUETZ P, MÜLLER C, BINGISSER R, BERGMANN A, TAMM M, CHRISTCRAIN M. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37: 145-152.
78. STOLZ D, CHRIST-CRAIN M, MORGENTHALER NG, LEUPPI J, MIEDINGER D, BINGISSER R, MÜLLER C, STRUCK J, MÜLLER B, TAMM M. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
79. STRUCK J, MORGENTHALER NG, BERGMANN A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26: 2500-2504.
80. TAPSON VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052.
81. TORBICKI A, PERRIER A, KONSTANTINIDES S, AGNELLI G, GALIÉ N, PRUSZCZYK P, BENGEL F, BRADY AJ, FERREIRA D, JANSSENS U, KLEPETKO W, MAYER E, REMY-JARDIN M, BASSAND JP, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL, ZAMORANO JL, ANDREOTTI F, ASCHERMAN M, ATHANASSOPOULOS G, DE SUTTER J, FITZMAURICE D, FORSTER T, HERAS M, JONDEAU G, KJELDSEN K, KNUUTI J, LANG I, LENZEN M, LOPEZ-SENDON J, NIHOYANNOPOULOS P, PEREZ ISLA L, SCHWEHR U, TORRACA L, VACHIERY JL; TASK FORCE FOR THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM OF THE EUROPEAN SOCIETY OF CARDIOLOGY. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
82. AGNELLI G, BECATTINI C. Acute pulmonary embolism. N Engl J Med 2010; 363: 266-274.
83. ADAM SS, KEY NS, GREENBERG CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113: 2878-2887.
84. STEIN PD, HULL RD, PATEL KC, OLSON RE, GHALI WA, BRANT R, BIEL RK, BHARADIA V, KALRA NK. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004; 140: 589-602.
85. LE GAL G, RIGHINI M, ROY PM, SANCHEZ O, AUJESKY D, BOUNAMEAUX H, PERRIER A. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171.
86. SÖHNE M, KAMPHUISEN PW, VAN MIERLO PJ, BÜLLER HR. Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatients. Thromb Haemost 2005; 94: 206-210.
87. MELANSON SE, LAPOSATA M, CAMARGO CA JR, CHEN AA, TUNG R, KRAUSER D, ANWARUDDIN S, BAGGISH A, CAMERON R, SLUSS P, LEWANDROWSKI KB, LEE-LEWANDROWSKI E, JANUZZI JL. Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. Arch Pathol Lab Med 2006; 130: 1326-1329.